Treatment of Pseudomonas aeruginosa Pneumonia in Severe Community-Acquired Pneumonia
Clinical Scenario
This protocol applies to adults with
severe community-acquired pneumonia (CAP) managed in the hospital setting who also meet at least one of the following validated risk criteria for
Pseudomonas aeruginosa:
- Prior respiratory isolation of P. aeruginosa
- Recent hospitalization within the last 90 days with receipt of parenteral antibiotics and locally validated risk factors for P. aeruginosa
Why Risk Factors Matter
Prior isolation of P. aeruginosa from the respiratory tract and recent parenteral antibiotic exposure are the most consistently identified risk factors for Pseudomonas infection in CAP. Empiric coverage for P. aeruginosa is only recommended when locally validated risk factors are present.
Treatment Approach
Management combines a standard severe inpatient CAP backbone regimen with the addition of empiric anti-pseudomonal coverage. Cultures should be obtained to allow deescalation or confirmation of the need for continued therapy.
The specific agents, combinations, and total duration are detailed in the full structured protocol.
Clinical Goals
The target endpoint is clinical stability within 5 days: resolution of vital sign abnormalities (heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature), ability to eat, and normal mentation. Failure to achieve stability within this window is associated with worse outcomes.
References
DOI: 10.1164/rccm.201908-1581ST
The most consistently strong individual risk factors for respiratory infection with MRSA or P. aeruginosa are prior isolation of these organisms, especially from the respiratory tract, and/or recent hospitalization and exposure to parenteral antibiotics.
The major additional risk factors for MRSA and P. aeruginosa identified in the literature are hospitalization and parenteral antibiotic exposure in the last 90 days.
We recommend clinicians only cover empirically for MRSA or P. aeruginosa in adults with CAP if locally validated risk factors for either pathogen are present.
Add coverage for P. aeruginosa and obtain cultures to allow deescalation or confirmation of need for continued therapy.
We believe that the duration of therapy for CAP due to suspected or proven MRSA or P. aeruginosa should be 7 days, in agreement with the recent hospital-acquired pneumonia and ventilator-associated pneumonia guidelines.
View source ↗